Copertura documentale

Il Quality Gate pubblico registra 21 supporti documentali, 4 fonti indipendenti e 3 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Baseline neutrophil-to-lymphocyte ratio is not associated with chemotherapy-induced nausea and vomiting in patients with breast cancer: A single-center retrospective cohort study. — PubMed / NCBI
• MERTK Inhibition Cooperates with Immunomodulatory Cyclophosphamide to Induce CXCL9+ Monocyte–Macrophage Programming and Durable Antitumor Immunity in Triple-Negative Breast Cancer — Crossref
• Artificial Intelligence application for diagnosis biomarkers, medicine designing and Chemotherapy for Breast Cancer (BC) using PEG linkage — Crossref
• Severe hyponatremia following low-dose cyclophosphamide in a patient with breast cancer: a case report — Crossref
• KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer — ClinicalTrials.gov
• Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer — ClinicalTrials.gov
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer — ClinicalTrials.gov
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer — ClinicalTrials.gov
• MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer. — Europe PMC
• MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer. — PubMed / NCBI
• Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation. — Europe PMC
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 — ClinicalTrials.gov

Collegamenti nel Knowledge Graph

• T-Cell Therapy for Advanced Breast Cancer — uses intervention
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) — uses intervention
• A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer — uses intervention
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer — uses intervention
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 86/100 · ultimo aggiornamento Settembre 29, 2026